Amgen, Inc.

Amgen, Inc. opened with a notable decline, continuing a trend of underperformance compared to the S&P 500. The company, with a market capitalization of approximately USD 197.4 billion, shows strong financial metrics but also significant leverage. Technical indicators present a mixed outlook amid ongoing market dynamics.

Amgen, Inc. faced a decline on March 19, 2026, contrasting with the S&P 500's performance. Over the past week and month, the stock has seen significant drops, yet it has shown resilience with a positive annual return. The company boasts strong financial metrics and high institutional ownership.

Amgen, Inc. experienced a decline on March 5, 2026, contrasting with a slight gain in the S&P 500. Despite a recent drop, Amgen has shown year-to-date growth, outperforming the index. The company maintains a strong financial position with high ROCE and interest coverage, alongside significant market capitalization.

Amgen, Inc. has achieved a new 52-week high, reflecting its strong performance with a notable increase over the past year. The company, with a market capitalization of USD 202 billion, demonstrates solid financial health, highlighted by a high return on equity and a manageable debt-to-equity ratio.

Amgen, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 202 billion, a P/E ratio of 21.00, and a return on equity of 100.80%, the company demonstrates significant growth and efficiency.

Amgen, Inc. has achieved a new 52-week high, reflecting strong performance with a 1-year growth rate significantly above the S&P 500. With a market cap of USD 202 billion, a P/E ratio of 21.00, and a return on equity of 100.80%, the company demonstrates solid financial health in the biotechnology sector.

Amgen, Inc. has recently adjusted its valuation metrics, with a P/E ratio of 22 and a Price to Book Value of 25.15. The company demonstrates strong financial health, evidenced by a high ROE of 116.13% and a PEG ratio of 0.27, amidst a competitive pharmaceutical landscape.

Amgen, Inc. has recently revised its evaluation amid current market dynamics, with its stock price at $291.16. The company has seen a 7.77% decline over the past year, underperforming compared to the S&P 500. Despite a year-to-date return of 11.71%, Amgen faces challenges in competitive performance.

Amgen, Inc. has recently experienced a change in its valuation grade, indicating a shift in market perception. Key financial metrics reveal a strong industry position, with a P/E ratio of 22 and a PEG ratio of 0.27, alongside significant operating cash flow and robust management efficiency.

Amgen, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 22 and a price-to-book value of 25.15. The company demonstrates strong financial metrics, including a high return on equity of 116.13% and a dividend yield of 3.18%, while facing market challenges reflected in its one-year return.

Amgen, Inc. has recently encountered a technical event known as a Death Cross, indicating potential shifts in market sentiment. Current indicators suggest a bearish outlook, despite a mixed performance over the past year. Investors are watching closely as Amgen shows short-term resilience against broader market trends.

Amgen, Inc. has recently revised its evaluation amid challenging market dynamics, with its stock showing a slight increase. Over the past year, the company has faced a decline, contrasting with broader market gains. Technical indicators present a mixed outlook, reflecting ongoing efforts to adapt to competitive pressures.